Zhejiang Ausun Pharmaceutical Co., Ltd.
SSE:603229.SS
9.34 (CNY) • At close June 11, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 795.288 | 816.765 | 764.547 | 569.698 | 409.249 | 307.915 | 243.885 | 240.188 | 198.842 | 262.666 | 201.417 | 120.949 | 58.931 |
| Kosten van de omzet
| 363.981 | 367.151 | 370.795 | 257.575 | 178.295 | 148.47 | 134.985 | 95.11 | 88.764 | 127.094 | 92.698 | 64.777 | 43.339 |
| Brutowinst
| 431.307 | 449.614 | 393.753 | 312.123 | 230.954 | 159.445 | 108.9 | 145.079 | 110.078 | 135.572 | 108.72 | 56.172 | 15.591 |
| Brutowinstmarge
| 0.542 | 0.55 | 0.515 | 0.548 | 0.564 | 0.518 | 0.447 | 0.604 | 0.554 | 0.516 | 0.54 | 0.464 | 0.265 |
| Onderzoek- en ontwikkelingskosten
| 100.419 | 78.058 | 67.073 | 68.825 | 50.77 | 47.747 | 34.375 | 29.841 | 23.484 | 31.46 | 26.922 | 13.954 | 4.109 |
| Algemene en administratieve kosten
| 49.961 | 52.104 | 39.773 | 33.763 | 27.156 | 24.255 | 17.204 | 16.075 | 9.005 | 11.237 | 31.267 | 29.043 | 8.58 |
| Verkoop- en marketingkosten
| 10.508 | 18.139 | 20.758 | 7.152 | 6.782 | 8.992 | 6.365 | 5.349 | 4.407 | 4.697 | 3.252 | 2.428 | 0.869 |
| Verkoop-, algemene en administratieve kosten
| 60.469 | 70.244 | 60.531 | 40.916 | 33.938 | 33.247 | 23.569 | 21.424 | 13.412 | 15.934 | 34.519 | 31.471 | 9.449 |
| Overige kosten
| 29.276 | 10.489 | 52.059 | 42.889 | 25.614 | 18.76 | 1.59 | -1.656 | 2.64 | 4.969 | 0.748 | -0.278 | -0.054 |
| Bedrijfskosten
| 190.164 | 158.79 | 179.664 | 152.63 | 110.321 | 99.754 | 78.387 | 67.232 | 52.959 | 62.63 | 73.405 | 31.643 | 9.459 |
| Bedrijfsresultaat
| 241.144 | 290.823 | 257.715 | 160.152 | 96.614 | 61.109 | 47.244 | 60.288 | 62.614 | 65.295 | 26.723 | 18.549 | 2.828 |
| Bedrijfsresultaat ratio
| 0.303 | 0.356 | 0.337 | 0.281 | 0.236 | 0.198 | 0.194 | 0.251 | 0.315 | 0.249 | 0.133 | 0.153 | 0.048 |
| Totaal overige inkomsten en kosten netto
| -0.944 | -0.061 | -1.856 | -0.761 | -13.391 | -0.507 | 0.079 | -9.543 | 2.64 | 4.969 | -4.434 | -5.134 | -2.693 |
| Inkomen voor belasting
| 240.2 | 290.762 | 255.859 | 159.391 | 95.498 | 60.602 | 47.323 | 60.142 | 65.255 | 70.264 | 27.471 | 18.271 | 2.774 |
| Inkomen voor belasting ratio
| 0.302 | 0.356 | 0.335 | 0.28 | 0.233 | 0.197 | 0.194 | 0.25 | 0.328 | 0.268 | 0.136 | 0.151 | 0.047 |
| Belastingkosten
| 33.409 | 36.86 | 20.483 | 13.461 | 8.662 | 4.215 | 3.459 | 7.131 | 7.926 | 9.398 | 5.97 | 2.718 | 0.48 |
| Nettowinst
| 206.791 | 253.902 | 235.376 | 145.93 | 86.836 | 56.387 | 43.864 | 53.012 | 57.328 | 60.865 | 21.501 | 15.553 | 2.294 |
| Nettowinstmarge
| 0.26 | 0.311 | 0.308 | 0.256 | 0.212 | 0.183 | 0.18 | 0.221 | 0.288 | 0.232 | 0.107 | 0.129 | 0.039 |
| WPA (Winst Per Aandeel)
| 0.25 | 0.31 | 0.42 | 0.26 | 0.17 | 0.11 | 0.083 | 0.11 | 0.15 | 0.17 | 0.14 | 0.11 | 0.027 |
| Verwaterde WPA
| 0.25 | 0.31 | 0.42 | 0.26 | 0.17 | 0.11 | 0.082 | 0.11 | 0.15 | 0.17 | 0.14 | 0.11 | 0.027 |
| EBITDA
| 311.622 | 339.628 | 296.888 | 191.294 | 122.528 | 86.047 | 71.235 | 80.149 | 83.515 | 86.079 | 43.407 | 32.497 | 8.953 |
| EBITDA ratio
| 0.392 | 0.416 | 0.388 | 0.336 | 0.299 | 0.279 | 0.292 | 0.334 | 0.42 | 0.328 | 0.216 | 0.269 | 0.152 |